An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1
By R. Verhaak, Katherine A. Hoadley, Elizabeth Purdom, V. Wang, Y. Qi, Matthew D. Wilkerson, C. Miller, Li Ding, Todd Golub, Jill P. Mesirov and 23 more. Cancer Cell, 2010
7,152 citations recorded by the source corpus.
SUMMARY The Cancer Genome Atlas Network recently catalogued recurrent genomic abnormalities in glioblastoma (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical and Mesenchymal subtypes and integrate multi-dimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define Classical, Mesenchymal, and Proneural, respectively. Gene signatures of normal brain cell types show a strong relation between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype with greatest benefit in Classical and no benefit in Proneural. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Subfields: Cancer Research, Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/188186e08f5dff92de2afe8fcd3dd1acee936ccb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Daniel C. Koboldt
- Jill P. Mesirov
- James T. Robinson
- Jeremy N. Rich
- Helga Thorvaldsdóttir
- Hannah Carter
- Gad Getz
- H. Ohgaki
In Genetics
- H. Ohgaki
- P. Kleihues
- Jeremy N. Rich
- Elaine R. Mardis
- M. Davis
- R. Jenkins
- McKinsey L. Goodenberger
- Hannah Carter
In Molecular Biology
- Peter W. Laird
- Eric S. Lander
- S. Baylin
- Aviv Regev
- Jill P. Mesirov
- Daniel C. Koboldt
- Hui Shen
- James T. Robinson
Citations in the corpus
- Complex heatmap visualization (2022, methodology): “As an example, the heatmap in Figure 2C includes genes that have significant differential expression in a glioblastoma cohort [25] with four subgroups (as the top annotation).”
- Comprehensive literature review and statistical considerations for microarray meta-analysis (2012, background): “Additional purposes of microarray meta-analysis include: (i) discover or validate disease subtypes (61–65); (ii) predict unknown gene functions (66,67) or transcriptional regulations (13); (iii) dimension reduction (68); (iv) gene clustering (69).”
- Genetics of adult glioma. (2012, background): “High expression of CHI3L1 and MET also characterize the mesenchymal subtype (20).”
- The Definition of Primary and Secondary Glioblastoma (2012, background): “Most IDH1 glioblastomas (11 of 12, 92%) show a proneural expression signature; conversely, approximately 30%of glioblastomas with a proneural signature are IDH1 (61).”
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018, methodology): “In addition, numerous independent investigators have used TCGA as a resource to support their own studies and to help interpret molecular testing of individual patients in a clinical setting (Huo et al., 2017; Verhaak et al., 2010).”
- MEF promotes stemness in the pathogenesis of gliomas (2012, neutral): “Malignant gliomas are highly aggressive cancers composed of a heterogeneous cell population, a fraction of which exhibits stem-like characteristics (Vescovi et al., 2006).”
- Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012, positive): “A statistic was calculated by an integration of the difference between the ECDFs, which is similar to the one used in GSEA, but based on absolute expression rather than differential expression (25).”
- Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “We also evaluated the distribution of somatic variants across the three molecular subtypes (Figure 1E) and confirmed the strong associations between subtypes and genomic abnormalities in previously reported driver genes (Brennan et al., 2013; Verhaak et al., 2010).”
- Pathway-based personalized analysis of cancer (2013, background): “Neural and proneural samples are thought to have better prognosis (20, 21); the pathway-based substratification reveals, however, that this notion is due to a subset of better survivors (logrank P value < 0.”